Leukemia Therapeutics Market Research Report ‚Äď Global Forecast till 2032

Leukemia Therapeutics Market Research Report Information by Type (Chemotherapy, Biological, Targeted, Radiation), by Application (Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia) - Forecast Till 2032

ID: MRFR/HC/5956-HCR | 110 Pages | Author: Rahul Gotadki | March 2024         

Leukemia Therapeutics Market Speak to Analyst Request a Free Sample

Leukemia Therapeutics Market Overview

The Leukemia Therapeutics Market Size was valued at USD 16.21 billion in 2022 and is projected to grow from USD 17.22 Billion in 2023 to USD 30.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.34% during the forecast period (2023 - 2032). 

The market will have high growth in the coming years if the market grows at the same pace. Cancer is a disease of genes caused by the uncontrolled growth of the cells in the body. The affected cells can further spread into another body site from that part through the blood and lymph system. It is known as blood cancer which commonly can happen to adults or children. Several types of leukemia are there, and leukemia therapeutics are used to treat them. The factors that improve the market are the rise of the older population, lifestyle changes, and others are some of the major causes of the market growth. However, the constraint that also hampers the growth pace is the high cost needed to develop new therapeutics. It makes an individual weak and loses the ability to fight any infection. The awareness among people regarding cancer disease and the sudden availability of detection and diagnosis will create more opportunities for the market. Common symptoms of this disease are fatigue, weight loss, frequent infections, easy bleeding or bruising, and some others.

Leukemia Therapeutics Market Segmentation

The global leukemia therapeutics market has been segmented into type, applications, and region.

Based on type, market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.

Based on applications, market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others.

The market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The leukemia therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.

Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to increase prevalence of leukemia.

The market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.

The Middle East & Africa has the least share of the leukemia therapeutics market.

Market of Leukemia Therapeutics Treatment Type Outlook

  • Chemotherapy

    • Alkylating Agents

    • Antimetabolites

    • Antitumor Antibiotics

    • Others

  • Biological Therapy

  • Targeted Therapy

  • Radiation Therapy

  • Stem Cell Transplant

  • Others

Market of Leukemia Therapeutics Application Outlook

  • Acute Lymphocytic Leukemia

  • Acute Myelogenous Leukemia

  • Chronic Lymphocytic Leukemia

  • Chronic Myelogenous Leukemia

  • Others

Market of Leukemia Therapeutics Region Outlook

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Middle East

    • Africa

Market of Leukemia Therapeutics, by Key Players

  • Eisai Co., Ltd (Japan)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • GlaxoSmithKline plc (UK)

  • Bristol-Myers Squibb Company (US)

  • Hoffmann-La Roche AG (Switzerland)

  • Sanofi S.A. (France)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Amgen Inc (US)

  • Takeda Pharmaceutical Company Ltd (Japan)

Recent Development

November 2023

Pfizer announced that its new breast cancer drug, palbociclib, has been approved by the FDA for the treatment of patients with HER2-positive metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that works by blocking the growth and spread of cancer cells.

Merck announced that its new breast cancer drug, pembrolizumab, has been approved by the FDA for the treatment of patients with triple-negative breast cancer (TNBC). Pembrolizumab is an immunotherapy drug that works by boosting the body's immune system to fight cancer cells.

Roche announced that its new breast cancer drug, tucatinib, has been approved by the FDA for the treatment of patients with HER2-positive advanced or metastatic breast cancer. Tucatinib is a TKI that works by blocking the HER2 protein, which is involved in the growth and spread of cancer cells.

October 2023

A new study published in the journal Nature Cancer finds that a combination of three drugs, including a PARP inhibitor, a CDK4/6 inhibitor, and a hormone therapy drug, is effective in shrinking tumors and prolonging survival in patients with advanced breast cancer.

Another study published in the journal Cancer Discovery finds that a new AI-powered algorithm is able to predict the risk of breast cancer recurrence more accurately than traditional methods. The algorithm takes into account a variety of factors, including the patient's tumor characteristics, medical history, and lifestyle.

September 2023

The American Cancer Society released its annual report on cancer statistics, which finds that the breast cancer death rate has decreased by 43% since 1990. The report also finds that the five-year survival rate for breast cancer is now 91%.

The National Cancer Institute awarded a grant to a team of researchers at Harvard University to develop a new type of breast cancer vaccine. The vaccine is designed to target a specific protein that is found on the surface of breast cancer cells.

May 2022

BeiGene is a worldwide science-driven biotechnology company that focuses on developing innovative and affordable medicines to improve treatment. It outcomes and access for patients worldwide. The company recently announced that the China National Medical Products Administration (NMPA) had granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia. The NMPA gave conditional approval for adult patients in this indication in December 2020.

April 2022

Curis, Inc., a biotechnology company, focuses on developing innovative therapeutics to treat cancer.

Intended Audience

  • Leukemia Therapeutics Manufacturers and Vendors

  • Research Organization

  • Various Research and Consulting Firms

  • Cancer Organization and Association

Report Scope:

Report Attribute/Metric Details
  Market Size   2032: USD 30.12 Billion
  CAGR   6.34%
  Base Year   2022
  Forecast Period   2023-2032
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Application, Regions
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Eisai Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd (Israel), Amgen Inc (US), and Takeda Pharmaceutical Company Ltd (Japan).
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers Increasing prevalence of leukemia Increasing older population, and availability of innovative therapies

Frequently Asked Questions (FAQ) :

The market is projected to grow at a 6.34% CAGR between 2023-2032

The Americas is expected to dominate the market.

The acute lymphocytic leukemia segment will dominate the market.

Increasing prevalence of leukemia, increasing older population, and availability of innovative therapies are boosting market growth.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players‚Äô financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response